Trial Profile
A 104-Week, Open-Label, Single-Group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH).
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms REACH
- 26 May 2010 Planned number of patients (60) added as reported by ClinicalTrials.gov record.
- 29 Apr 2009 New trial record